BioSpace News Archive

Quidel Corporation announced today that the company has received the CE Mark for its innovative Savanna® multiplex molecular analyzer and Savanna® RVP4 Assay (Respiratory Viral Panel-4).

48Hour Discovery Inc and RayzeBio today announced the companies have entered a strategic research collaboration to discover and develop novel peptide-based radiopharmaceuticals for the treatment of cancer.

Tavanta Therapeutics, a specialty pharmaceutical company, today announced new additions to its executive and senior leadership teams with the appointment of Andreas Maetzel, M.D., PhD as chief medical officer (CMO) and the promotion of Elizabeth Manning Duus, PhD to vice president of clinical development.

Venus Concept Inc. today announced that management will participate in the Ladenburg Thalmann Healthcare Conference. Management will present at the conference on Tuesday, July 13th at 2:30 p.m. Eastern Time.

Cambridge Diagnostic Imaging, CaDi, launches Lycobrain™, a first-in class nutraceutical to reboot and support brain functions, together with the development of a companion point-of-care diagnostic blood test for the assessment of tissue oxygenation.

Hochuen Medical Technology Co., Ltd. has raised a 40 million Yuan Series A round of financing led by Qiming Venture Partners as the sole investor.

Selvita - one of the largest preclinical contract research organizations in Europe, announced the initiation of the construction of its own research centre in Krakow.

According to our new market research study on “Dermatology Treatment Devices Market to 2027 – COVID-19 Impact and Global Analysis – by Product Type, Application, and End User,” the market is expected to reach US$ 8,800.07 million by 2027 from US$ 5,320.73 million in 2019; it is estimated to grow at a CAGR of 6.7% during 2020–2027.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the addition of three world-class scientists and clinical researchers to its Alzheimer’s Disease Scientific Advisory Board.

KCAS Bioanalytical and Biomarker Services, a laboratory services focused contract research organization is pleased to announce the expansion of their Biopharmaceutical Services team.